Following Sun Pharma's $3.2 billion acquisition of Ranbaxy in April, and well as quality issues that resulted in the U.S. FDA barring four Ranbaxy facilties from exporting drugs to the U.S., Ranbaxy is "reshuffling" its management execs.
According to ET sources, Dale Adkisson has stepped down from the position of head of global quality, and will be replaced by Arno Gessner. Adkisson, who had come to Ranbaxy in 2010 from a position with previous owners Daiichi Sankyo, had been looked to as the "go-to man" for solving Ranbaxy's run-ins with the FDA. Additionally, Alexander Gebauer has been appointed as the new head of global research and development.
